Forgot your password?
The phase 3 study evaluated the drug for up to five years in patients with moderate-to-severe cases
More than 16 million people in the US are affected by the long-term inflammatory skin condition
The inflammatory skin disease affects up to 10% of adults and 20% of children worldwide
The IL-23 inhibitor is being evaluated in adults with special site involvement
Scalp psoriasis affects approximately 80% of patients with plaque psoriasis
Approximately 7.3% of adults in the US are affected by the inflammatory skin condition
Anzupgo is now the first topical treatment specifically indicated for this patient population in the EU
The results showed that improvements observed with the drug were maintained at week 96
The inflammatory skin disease affects approximately 40 million people globally
Over 100,640 people are expected to be diagnosed with melanoma in the US this year